AstraZeneca Pharma India Q2 Revenue Up 30% to ₹7,291 Mn

AstraZeneca Pharma India announced its Q2 FY'26-27 financial results, reporting a strong 30% growth in total revenue from operations, reaching INR 7,291 Mn. For the first half of FY'26-27 (H1 2026-27), total revenue from operations grew by 30% to INR 14,119 Mn. The company highlighted disciplined execution, operational efficiency, portfolio expansion, and adoption of innovative therapies as drivers for this performance. Key therapy areas contributing to growth include Oncology, Biopharmaceuticals, and Rare Disease. AstraZeneca also secured three new regulatory approvals in Q2, including for Trastuzumab deruxtecan and Benralizumab, reinforcing its market leadership. Strategic initiatives include MoUs with Andhra Pradesh and Telangana for oncology and lung cancer screening programs, respectively, and launches of K+ Connect and India Coronary Conquest 2026.